)
)
)
Aureka Biotechnologies
Aureka Biotechnologies is a fully integrated biotechnology company, which develops life-saving, best-in-class antibody therapeutics at scale, powered by generative AI and high-throughput proprietary data generation platform. Our high-value use cases include single paratope antibodies binding multiple family members, potent receptor agonists, pH-dependent sweeping antibodies, rapid internalizing biparatopic antibodies for ADCs, and epitope-specific de novo design for challenging targets such as GPCRs.
Our internal pipelines include:
(a) ActRIIA/B dual antagonist for obesity and cardiometabolic disorders (currently DC, in
discussions to out-license),
(b) PD-1 agonist for severe inflammatory and autoimmune disorders (DC in Q1 2026, IND in Q1 2027, clinical POC in 2H 2027).
(c) BIC sweeping antibody therapeutic for autoimmune diseases.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)